Patheon signs up to manufacture Flexion's lead drug

Contract drugmaker Patheon inked a deal to manufacture Flexion Therapeutics' ($FLXN) top prospect as it moves through clinical development. The treatment, FX006, is an injectable steroid treatment for osteoarthritis pain, and its promise helped Flexion pull off a $60 million IPO last year. Under the latest agreement, Patheon will use its Swindon, U.K., site to manufacture doses of FX006 to support the drug's ongoing Phase III trial. More

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.